Estrella Immunopharma, Inc. (ESLAW) revenue by segment
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-2.08%)
Close on Nov 18, 2026Market cap $14.48MP/E –Yield –
See a number that looks wrong?